scholarly journals Protective Efficacy of a Single Immunization of a Chimeric Adenovirus Vector-Based Vaccine against Simian Immunodeficiency Virus Challenge in Rhesus Monkeys

2009 ◽  
Vol 83 (18) ◽  
pp. 9584-9590 ◽  
Author(s):  
Dan H. Barouch ◽  
Jinyan Liu ◽  
Diana M. Lynch ◽  
Kara L. O'Brien ◽  
Annalena La Porte ◽  
...  
Keyword(s):  
Simian Immunodeficiency Virus ◽  
Rhesus Monkeys ◽  
Recombinant Adenovirus ◽  
Protective Efficacy ◽  
Hypervariable Region ◽  
Adenovirus Vector ◽  
Single Shot ◽  
Virus Challenge ◽  
Immunodeficiency Virus ◽  
Potential Vaccine

ABSTRACT Rare serotype and chimeric recombinant adenovirus (rAd) vectors that evade anti-Ad5 immunity are currently being evaluated as potential vaccine vectors for human immunodeficiency virus type 1 and other pathogens. We have recently reported that a heterologous rAd prime-boost regimen expressing simian immunodeficiency virus (SIV) Gag afforded durable partial immune control of an SIV challenge in rhesus monkeys. However, single-shot immunization may ultimately be preferable for global vaccine delivery. We therefore evaluated the immunogenicity and protective efficacy of a single immunization of chimeric rAd5 hexon hypervariable region 48 (rAd5HVR48) vectors expressing SIV Gag, Pol, Nef, and Env against a homologous SIV challenge in rhesus monkeys. Inclusion of Env resulted in improved control of peak and set point SIV RNA levels following challenge. In contrast, DNA vaccine priming did not further improve the protective efficacy of rAd5HVR48 vectors in this system.

scholarly journals Clinical Measles after Measles Virus Challenge in Simian Immunodeficiency Virus–Infected Measles Virus–Vaccinated Rhesus Monkeys

2007 ◽  
Vol 196 (12) ◽  
pp. 1784-1793 ◽  
Author(s):  
Sallie R. Permar ◽  
Srinivas S. Rao ◽  
Yue Sun ◽  
Saran Bao ◽  
Adam P. Buzby ◽  
...  
Keyword(s):  
Simian Immunodeficiency Virus ◽  
Rhesus Monkeys ◽  
Measles Virus ◽  
Virus Challenge ◽  
Immunodeficiency Virus

scholarly journals Recombinant Mycobacterium bovis BCG Prime-Recombinant Adenovirus Boost Vaccination in Rhesus Monkeys Elicits Robust Polyfunctional Simian Immunodeficiency Virus-Specific T-Cell Responses

2009 ◽  
Vol 83 (11) ◽  
pp. 5505-5513 ◽  
Author(s):  
Mark J. Cayabyab ◽  
Birgit Korioth-Schmitz ◽  
Yue Sun ◽  
Angela Carville ◽  
Harikrishnan Balachandran ◽  
...  
Keyword(s):  
T Cell ◽  
Simian Immunodeficiency Virus ◽  
Mycobacterium Bovis ◽  
High Frequency ◽  
Rhesus Monkeys ◽  
Recombinant Adenovirus ◽  
T Cell Responses ◽  
Cellular Responses ◽  
Cell Responses ◽  
Immunodeficiency Virus

ABSTRACT While mycobacteria have been proposed as vaccine vectors because of their persistence and safety, little has been done systematically to optimize their immunogenicity in nonhuman primates. We successfully generated recombinant Mycobacterium bovis BCG (rBCG) expressing simian immunodeficiency virus (SIV) Gag and Pol as multigenic, nonintegrating vectors, but rBCG-expressing SIV Env was unstable. A dose and route determination study in rhesus monkeys revealed that intramuscular administration of rBCG was associated with local reactogenicity, whereas intravenous and intradermal administration of 106 to 108 CFU of rBCG was well tolerated. After single or repeat rBCG inoculations, monkeys developed high-frequency gamma interferon enzyme-linked immunospot responses against BCG purified protein derivative. However, the same animals developed only modest SIV-specific CD8+ T-cell responses. Nevertheless, high-frequency SIV-specific cellular responses were observed in the rBCG-primed monkeys after boosting with recombinant adenovirus 5 (rAd5) expressing the SIV antigens. These cellular responses were of greater magnitude and more persistent than those generated after vaccination with rAd5 alone. The vaccine-elicited cellular responses were predominantly polyfunctional CD8+ T cells. These findings support the further exploration of mycobacteria as priming vaccine vectors.

scholarly journals Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge

2004 ◽  
Vol 85 (5) ◽  
pp. 1191-1201 ◽  
Author(s):  
Donatella R. M. Negri ◽  
Silvia Baroncelli ◽  
Stefania Catone ◽  
Antonella Comini ◽  
Zuleika Michelini ◽  
...  
Keyword(s):  
Simian Immunodeficiency Virus ◽  
Viral Vectors ◽  
Semliki Forest Virus ◽  
Protective Efficacy ◽  
Cynomolgus Monkeys ◽  
Virus Challenge ◽  
Vector Vaccine ◽  
Modified Vaccinia Virus Ankara ◽  
Wide Range ◽  
Immunodeficiency Virus

We investigated the protective efficacy of a systemic triple vector (DNA/rSFV/rMVA)-based vaccine against mucosal challenge with pathogenic simian immunodeficiency virus (SIV) in cynomolgus monkeys. Animals were immunized at week 0 with DNA (intradermally), at weeks 8 and 16 with recombinant Semliki Forest virus (rSFV, subcutaneously) and finally, at week 24, with recombinant modified vaccinia virus Ankara strain (rMVA, intramuscularly). Both DNA and recombinant viral vectors expressed a wide range of SIV proteins (Gag, Pol, Tat, Rev, Env and Nef). This immunization strategy elicited cell-mediated rather than humoral responses that were especially increased following the last boost. Upon intrarectal challenge with pathogenic SIVmac251, three of the four vaccinated monkeys dramatically abrogated virus load to undetectable levels up to 41 weeks after challenge. A major contribution to this vaccine effect appeared to be the T-cell-mediated immune response to vaccine antigens (Gag, Rev, Tat, Nef) seen in the early phase of infection in three of the four vaccinated monkeys. Indeed, the frequency of T-cells producing antigen-induced IFN-γ mirrored virus clearance in the vaccinated and protected monkeys. These results, reminiscent of the efficacy of live attenuated virus vaccines, suggest that vaccination with a combination of many viral antigens can induce a robust and stable vaccine-induced immunity able to abrogate virus replication.

Sign in / Sign up

Export Citation Format

Share Document